SM Energy Company announced it will release its third quarter 2026 financial and operating results after market close on November 3, 2026. The company will hold a conference call to discuss the results on November 4 at 8:00 a.m. MT. Investors can join the call via registration and access the webcast on the company website. SM Energy operates major oil and gas assets in key U.S. shale basins and focuses on operational excellence and shareholder returns.
SM Energy's upcoming third quarter 2026 conference call is scheduled for November 4, 2026. For readers following the energy sector, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: out of 38 priced US energy stocks, 29 rose and 9 fell. Notable movers include Valero Energy Corporation (VLO) at USD 420.00 with a 3.37% increase, Cameco (CCJ) at USD 87.58 up 2.82%, and Tidewater Inc (TDW) at USD 84.38 up 2.37%.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
